Hepatitis C

RBX2660 is a standardized, stabilized, investigational microbiota-based live biotherapeutic.

This risk also increased with age and was amplified in patients with HCV compared to patients without HCV.

Concurrent metabolic syndrome was independently linked to a worse overall and recurrence-free survival rates.

In the group positive for HCV by RNA testing in the emergency department, the linkage to care was just 44.1%, compared to 67.6% for patients in outpatient clinics and 50.9% for patients in inpatient units.

The inter-relationship of HPCs, HSCs, and macrophages was influenced by the stage of fibrosis, but not BMI.

The investigators sequenced HBsAg and found no amino acid substitution.

It is the first FDA-approved product indicated to improve kidney function in adults with HRS.

Model results were sensitive to the probability of hernia recurrence and hernia incarceration and utility decrement in the symptomatic hernia state.

Patients with both COVID-19 and HBV had a significantly higher in-hospital mortality rate and were more likely to develop severe disease compared to patients with only COVID-19 infections.

The highest global cirrhosis prevalence was found in the East and Southeast Asia, mainly caused by high levels of hepatitis prevalence in those areas.

The investigators found that the HCV viremia/HIV-positive group had a higher risk of HCV mother-to-child transmission.

The odds of HBV seroprevalence in participants with no or primary education was higher than individuals with secondary level education or higher.

NAFLD patients had a 13% higher risk of developing IBS after multivariable adjustment compared to patients without NAFLD.

In the study, 60.4% achieved resolution of ascites, encephalopathy, and absence of recurrent variceal bleeding for at least 12 months.

For liver-related deaths, 90% were from liver cancer, while the most common cause of non-liver-related deaths was malignancy.

The treatment is the first pediatric indication of the treatment and the first treatment for younger patients with cGVHD.

Occult HBV infection prevalence in blood donors was 0.06% in low-endemicity countries, 0.12% in intermediate-endemicity countries, and 0.98% in high-endemicity countries.

Some noticeable presenting features included jaundice, vomiting, and diarrhea.

The 10-year cumulative incidences for HCC and mortality were significantly higher in the HBV cohort with heavy alcoholism than it was for either HBV alone or alcoholism alone.

Investigators articulated the development and validation of an enzyme-linked immunoassay against hepatitis C virus (HCV). They suggest the implementation of this low cost assay among at-risk populations.

The increase does not appear to have a negative impact on post transplant survival, investigators say.

The goal for many is to eradicate HCV by the year 2030.

Dr. Sanyal talks about the importance in having ongoing real-world data for NAFLD and NASH.

ALT fluctuations remained stable for patients with NAFLD throughout disease progression.

The overall prevalence of NAFLD was 40.6%, with every NAFLD patient having a BMI of at least 25.

The results are consistent with the original analysis from 2019, where the treatment resulted in a statistically significant effect on fibrosis improvement.

Washington DC, Hawaii, Oklahoma, California, Tennessee, West Virginia, Mississippi, Oregon, Washington, Louisiana, Kentucky, and New York all had HBV-related mortality rates higher than the national average.

Tenofovir was linked to a decreased incidence rate of HCC compared to entecavir. However, this difference was not considered statistically significant.

Between 2015-2019 the number of HBV-related deaths increased by 2.9%.

Acute hepatitis of unknown etiology is not reportable in the US, making it difficult to understand whether recent levels are now reaching historic levels.